JP2010501164A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010501164A5 JP2010501164A5 JP2009524844A JP2009524844A JP2010501164A5 JP 2010501164 A5 JP2010501164 A5 JP 2010501164A5 JP 2009524844 A JP2009524844 A JP 2009524844A JP 2009524844 A JP2009524844 A JP 2009524844A JP 2010501164 A5 JP2010501164 A5 JP 2010501164A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- identity
- cdr2
- set forth
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 101710098483 C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 8
- 102100032957 C5a anaphylatoxin chemotactic receptor 1 Human genes 0.000 claims 8
- 101000867983 Homo sapiens C5a anaphylatoxin chemotactic receptor 1 Proteins 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 239000012634 fragment Substances 0.000 claims 3
- 210000004408 hybridoma Anatomy 0.000 claims 3
- 210000000265 leukocyte Anatomy 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 238000000338 in vitro Methods 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 238000013508 migration Methods 0.000 claims 2
- 230000005012 migration Effects 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 238000003745 diagnosis Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US83963406P | 2006-08-22 | 2006-08-22 | |
| US60/839,634 | 2006-08-22 | ||
| PCT/AU2007/001207 WO2008022390A1 (en) | 2006-08-22 | 2007-08-22 | Anti-c5ar antibodies with improved properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010501164A JP2010501164A (ja) | 2010-01-21 |
| JP2010501164A5 true JP2010501164A5 (cg-RX-API-DMAC7.html) | 2010-09-30 |
| JP5162587B2 JP5162587B2 (ja) | 2013-03-13 |
Family
ID=39106388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009524844A Expired - Fee Related JP5162587B2 (ja) | 2006-08-22 | 2007-08-22 | 改良された特性を持つ坑−Ｃ５ａＲ抗体 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8337852B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2051997B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP5162587B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20090053899A (cg-RX-API-DMAC7.html) |
| CN (2) | CN104059149B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2007288118A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BRPI0715703A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2660156A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2570153T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL196960A0 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2009001914A (cg-RX-API-DMAC7.html) |
| NO (1) | NO20091181L (cg-RX-API-DMAC7.html) |
| RU (1) | RU2009110154A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008022390A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA200900954B (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4559081B2 (ja) | 2002-01-25 | 2010-10-06 | ジーツー セラピーズ リミテッド | 抗Ｃ５ａＲ抗体及びその使用 |
| WO2008022390A1 (en) | 2006-08-22 | 2008-02-28 | G2 Inflammation Pty Ltd | Anti-c5ar antibodies with improved properties |
| EP2254911B1 (en) | 2008-02-20 | 2015-11-25 | Novo Nordisk A/S | Humanized anti-c5ar antibodies |
| BR112012027900A2 (pt) | 2010-04-30 | 2020-05-12 | Alexion Pharmaceuticals, Inc. | Anticorpos anti-c5a e métodos para usar os anticorpos |
| US11130801B2 (en) * | 2011-01-13 | 2021-09-28 | Case Western Reserve University | Method for inhibiting platelet derived growth factor signaling with C3aR or C5aR antibodies |
| EP3798230B1 (en) | 2011-06-06 | 2022-08-03 | Novo Nordisk A/S | Therapeutic antibodies |
| KR102006997B1 (ko) * | 2012-07-03 | 2019-08-02 | 한국생명공학연구원 | ＩｇＧ Ｆｃ 위치선택적 결합 펩티드 및 이를 포함하는 하이브리드 분자 |
| CN106957366B (zh) * | 2016-01-12 | 2022-02-01 | 上海昀怡健康科技发展有限公司 | 一种C5aR抗体及其制备方法和应用 |
| JP6923212B2 (ja) * | 2016-02-17 | 2021-08-18 | 国立大学法人 東京医科歯科大学 | 動脈硬化性疾患の発症の予測因子および検査方法 |
| CN106614260B (zh) * | 2016-09-06 | 2019-11-08 | 广东省人民医院 | 一种C5aR基因敲除小鼠cGVHD模型的建立方法 |
| ES2893769T3 (es) * | 2017-04-03 | 2022-02-10 | Inflarx Gmbh | Tratamiento de enfermedades inflamatorias con inhibidores de la actividad de C5a |
| US10376595B2 (en) | 2017-04-03 | 2019-08-13 | Inflarx Gmbh | Treatment of inflammatory diseases with inhibitors of C5a activity |
| TWI869528B (zh) * | 2020-01-13 | 2025-01-11 | 美商威特拉公司 | C5ar1抗體分子及其用途 |
| JP2024502863A (ja) | 2021-01-13 | 2024-01-23 | ビステラ， インコーポレイテッド | ヒト化補体５ａ受容体１抗体及びその使用方法 |
| US12180274B2 (en) | 2023-05-26 | 2024-12-31 | Inflarx Gmbh | Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154598B (nl) * | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3817827A (en) | 1972-03-30 | 1974-06-18 | Scott Paper Co | Soft absorbent fibrous webs containing elastomeric bonding material and formed by creping and embossing |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4704362A (en) * | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| EP0279582A3 (en) * | 1987-02-17 | 1989-10-18 | Pharming B.V. | Dna sequences to target proteins to the mammary gland for efficient secretion |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| JPH02262599A (ja) | 1989-01-03 | 1990-10-25 | Merck & Co Inc | ヒト多形核白血球からの精製Ｃ５ａレセプター |
| AU641673B2 (en) | 1989-06-29 | 1993-09-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
| US5633076A (en) * | 1989-12-01 | 1997-05-27 | Pharming Bv | Method of producing a transgenic bovine or transgenic bovine embryo |
| US5284746A (en) | 1990-02-08 | 1994-02-08 | Zymogenetics, Inc. | Methods of producing hybrid G protein-coupled receptors |
| WO1992003918A1 (en) | 1990-08-29 | 1992-03-19 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5194594A (en) * | 1990-09-07 | 1993-03-16 | Techniclone, Inc. | Modified antibodies |
| US5173414A (en) * | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
| CA2102511A1 (en) | 1991-05-14 | 1992-11-15 | Paul J. Higgins | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69334287D1 (de) | 1992-09-25 | 2009-07-09 | Avipep Pty Ltd | Zielmoleküle-bindende Polypeptide bestehend aus einer IG-artigen VL Domäne die an eine IG-artige VH Domäne gebunden ist |
| DE69329503T2 (de) | 1992-11-13 | 2001-05-03 | Idec Pharma Corp | Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma |
| US5514555A (en) | 1993-03-12 | 1996-05-07 | Center For Blood Research, Inc. | Assays and therapeutic methods based on lymphocyte chemoattractants |
| US5480974A (en) | 1993-06-18 | 1996-01-02 | The Scripps Research Institute | Antibodies to human C5a receptor |
| US5827690A (en) * | 1993-12-20 | 1998-10-27 | Genzyme Transgenics Corporatiion | Transgenic production of antibodies in milk |
| US5861272A (en) * | 1995-06-02 | 1999-01-19 | Human Genome Sciences, Inc. | C5A receptor |
| JPH08109200A (ja) | 1994-08-19 | 1996-04-30 | Takeda Chem Ind Ltd | 抗Ｃ５ａレセプター抗体、その製造法および用途 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| MX9709338A (es) | 1995-06-05 | 1998-02-28 | Incyte Pharma Inc | Receptor de transmembrana-siete de tipo c5a. |
| JPH09124509A (ja) * | 1995-10-27 | 1997-05-13 | Sumitomo Electric Ind Ltd | 肝炎治療剤 |
| CA2722378C (en) | 1996-12-03 | 2015-02-03 | Amgen Fremont Inc. | Human antibodies that bind tnf.alpha. |
| EP0972027A1 (en) | 1997-01-31 | 2000-01-19 | Incyte Pharmaceuticals, Inc. | Human c5a-like receptor |
| US8007798B2 (en) * | 1997-11-21 | 2011-08-30 | Genentech, Inc. | Treatment of complement-associated disorders |
| AU2002231194A1 (en) | 2000-11-07 | 2002-05-21 | Genetics Institute, Llc | G protein-coupled receptor protein and nucleic acid molecules and uses therefor |
| ES2389251T3 (es) | 2000-12-19 | 2012-10-24 | Altor Bioscience Corporation | Animales transgénicos que comprenden un sistema inmunitario humanizado |
| WO2002061087A2 (en) * | 2000-12-19 | 2002-08-08 | Lifespan Biosciences, Inc. | Antigenic peptides, such as for g protein-coupled receptors (gpcrs), antibodies thereto, and systems for identifying such antigenic peptides |
| ATE360441T1 (de) * | 2001-08-17 | 2007-05-15 | Tanox Inc | Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen |
| US7193070B2 (en) | 2001-09-27 | 2007-03-20 | Merck & Co., Inc. | Isolated DNA molecules encoding humanized calcitonin gene-related peptide receptor, related non-human transgenic animals and assay methods |
| US7241444B2 (en) * | 2002-01-18 | 2007-07-10 | Pierre Fabre Medicament | Anti-IGF-IR antibodies and uses thereof |
| JP4559081B2 (ja) * | 2002-01-25 | 2010-10-06 | ジーツー セラピーズ リミテッド | 抗Ｃ５ａＲ抗体及びその使用 |
| AU2003300776A1 (en) | 2002-09-09 | 2004-05-25 | Omeros Corporation | G protein coupled receptors and uses thereof |
| DE10303664A1 (de) * | 2003-01-23 | 2004-08-12 | Nemod Immuntherapie Ag | Erkennungsmoleküle zur Behandlung und Detektion von Tumoren |
| WO2005060739A1 (en) | 2003-12-24 | 2005-07-07 | G2 Inflammation Pty Ltd | Transgenic non-human mammal comprising a polynucleotide encoding human or humanized c5ar |
| ATE497508T1 (de) * | 2004-10-01 | 2011-02-15 | Max Planck Gesellschaft | Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper |
| WO2008022390A1 (en) | 2006-08-22 | 2008-02-28 | G2 Inflammation Pty Ltd | Anti-c5ar antibodies with improved properties |
| JP2010501165A (ja) | 2006-08-22 | 2010-01-21 | ジーツー インフラメイション プロプライエタリー リミテッド | 抗体の作製方法 |
| EP2254911B1 (en) * | 2008-02-20 | 2015-11-25 | Novo Nordisk A/S | Humanized anti-c5ar antibodies |
-
2007
- 2007-08-22 WO PCT/AU2007/001207 patent/WO2008022390A1/en not_active Ceased
- 2007-08-22 MX MX2009001914A patent/MX2009001914A/es not_active Application Discontinuation
- 2007-08-22 US US12/375,876 patent/US8337852B2/en not_active Expired - Fee Related
- 2007-08-22 RU RU2009110154/10A patent/RU2009110154A/ru unknown
- 2007-08-22 EP EP07784844.8A patent/EP2051997B1/en not_active Not-in-force
- 2007-08-22 EP EP12155157.6A patent/EP2455404B1/en not_active Not-in-force
- 2007-08-22 CA CA002660156A patent/CA2660156A1/en not_active Abandoned
- 2007-08-22 JP JP2009524844A patent/JP5162587B2/ja not_active Expired - Fee Related
- 2007-08-22 CN CN201410134435.5A patent/CN104059149B/zh not_active Expired - Fee Related
- 2007-08-22 ZA ZA200900954A patent/ZA200900954B/xx unknown
- 2007-08-22 AU AU2007288118A patent/AU2007288118A1/en not_active Abandoned
- 2007-08-22 ES ES12155157T patent/ES2570153T3/es active Active
- 2007-08-22 BR BRPI0715703-7A2A patent/BRPI0715703A2/pt not_active IP Right Cessation
- 2007-08-22 CN CN200780031002.5A patent/CN101506237B/zh not_active Expired - Fee Related
- 2007-08-22 KR KR1020097003924A patent/KR20090053899A/ko not_active Withdrawn
-
2009
- 2009-02-09 IL IL196960A patent/IL196960A0/en unknown
- 2009-03-20 NO NO20091181A patent/NO20091181L/no not_active Application Discontinuation